In addition, striatal and nigral CHRM4 signaling leads to multilevel inhibition of striato-nigral pathways which can result in an attenuation of dyskinesia (Brugnoli et al., 2020), which links the CHRM4 to dopaminergic activity in the CNS (Porras et al., 2014). This evidence concerns the gene CHRM4 and drug-induced dyskinesia.